A large-scale study has revealed the impact of germline variants on proteins in 10 cancer types. Scientists from the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) conducted a precision proteogenomic analysis in a pan-cancer study with data from 1,064 patients, identifying tumor heterogeneity and tumorigenesis associated with heritable genetic alterations. The results provide a broad view of cancer risk that could be useful for patient stratification and the design of prevention strategies.
Eli Lilly & Co. has disclosed new calcium/calmodulin-dependent 3’,5’-cyclic nucleotide phosphodiesterase 1 (PDE1) inhibitors reported to be useful for the treatment of chronic kidney disease, Alzheimer’s disease, Parkinson’s disease, schizophrenia, heart failure, pulmonary hypertension, myocardial infarction and ischemic stroke, among others.
Multiomic Health Ltd. and Alloy Therapeutics Inc. have signed a memorandum of understanding to jointly discover and develop first-in-class renal tissue-targeting drugs. Precision medicines for chronic renal conditions targeted to the kidney tissue of specific patient subpopulations are expected to improve efficacy and safety compared to conventional systemic drugs.
Shenzhen Zhongge Biotechnology Co. Ltd. has synthesized AMP-activated protein kinase α1β1γ1 activators reported to be useful for the treatment of acute kidney injury, alopecia, chronic kidney disease, diabetes type 2, diabetic nephropathy, dyslipidemia and obesity.
Focal segmental glomerulosclerosis (FSGS) is a kidney disease that leads to renal failure, and it affects individuals from different ancestries, the highest prevalence being among African and African American populations. DNA samples from 726 patients with FSGS were obtained and DNA sequencing was performed in the search of mutations tied to FSGS compared to a large pool of control populations.
Nephronophthisis (NPH) is a recessive cystic kidney disease responsible for 10% to 20% of pediatric end-stage renal disease cases. NPHP1 (nephrocystin 1) is the most frequently implicated among over 20 known causative genes. However, the pathogenesis of NPH remains unclear, and no effective therapies are available.
Multiple endogenous retroviruses (ERVs) in human DNA may be programmed to activate as cancer therapy. A recent study, led by scientists at the Dana-Farber Cancer Institute, expanded on a previously reported case of kidney cancer cure after hematopoietic stem cell transplantation attributed to the expression of an ERV driven by the hypoxia-inducible factor 2 (HIF2). The question was whether this finding might play out with different ERVs and different types of cancer through HIF.
Protein palmitoylation is a post-translational modification catalyzed by a series of enzymes called zinc finger DHHC (ZDHHC) palmitoyltransferases. Scientists from Guangzhou Medical University and affiliated organizations aimed to assess the function of protein palmitoylation in renal fibrosis, a common pathway leading to end-stage chronic kidney disease.
Shenzhen Zhongge Biotechnology Co. Ltd. has divulged AMP-activated protein kinase α1β1γ1 activators reported to be useful for the treatment of acute kidney injury, alopecia, chronic kidney disease, type 2 diabetes, diabetic nephropathy, dyslipidemia and obesity.
RSS
